◎ Sugi Atlas

Atlas / Gene / GPR151

GPR151

gene
On this page

Also known as PGR7GALR4

Summary

GPR151 (G protein-coupled receptor 151, HGNC:23624) is a protein-coding gene on chromosome 5q32, encoding G-protein coupled receptor 151 (Q8TDV0). Proton-sensing G-protein coupled receptor.

This gene encodes an orphan member of the class A rhodopsin-like family of G-protein-coupled receptors (GPCRs). Within the rhodopsin-like family, this gene is a member of the SOG subfamily that includes somatostatin, opioid, galanin, and kisspeptin receptors. The orthologous mouse gene has a restricted pattern of neuronal expression which is induced following nerve injury. All GPCRs have a transmembrane domain that includes seven transmembrane alpha-helices. A general feature of GPCR signaling is the agonist-induced conformational change in the receptor, leading to activation of the heterotrimeric G protein. The activated G protein then binds to and activates numerous downstream effector proteins, which generate second messengers that mediate a broad range of cellular and physiological processes.

Source: NCBI Gene 134391 — RefSeq curated summary.

At a glance

  • GWAS associations: 1
  • Clinical variants (ClinVar): 82 total
  • Druggable target: yes
  • MANE Select transcript: NM_194251

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:23624
Approved symbolGPR151
NameG protein-coupled receptor 151
Location5q32
Locus typegene with protein product
StatusApproved
AliasesPGR7, GALR4
Ensembl geneENSG00000173250
Ensembl biotypeprotein_coding
OMIM618487
Entrez134391

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000311104

RefSeq mRNA: 1 — MANE Select: NM_194251 NM_194251

CCDS: CCDS34266

Canonical transcript exons

ENST00000311104 — 1 exons

ExonStartEnd
ENSE00001202245146513144146516190

Expression profiles

Bgee: expression breadth broad, 16 present calls, max score 49.82.

Top tissues by expression

126 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
prefrontal cortexUBERON:000045149.82gold quality
C1 segment of cervical spinal cordUBERON:000646947.66gold quality
Brodmann (1909) area 9UBERON:001354046.53gold quality
superior frontal gyrusUBERON:000266146.43silver quality
primary visual cortexUBERON:000243645.01silver quality
ganglionic eminenceUBERON:000402344.57silver quality
dorsolateral prefrontal cortexUBERON:000983444.29gold quality
frontal cortexUBERON:000187044.20gold quality
cortical plateUBERON:000534343.77gold quality
cerebral cortexUBERON:000095641.80gold quality
colonic epitheliumUBERON:000039741.35gold quality
anterior cingulate cortexUBERON:000983540.67gold quality
bone marrow cellCL:000209240.30gold quality
calcaneal tendonUBERON:000370138.86gold quality
stromal cell of endometriumCL:000225538.78gold quality
granulocyteCL:000009437.02gold quality
substantia nigraUBERON:000203836.79silver quality
ventricular zoneUBERON:000305336.48gold quality
skeletal muscle tissueUBERON:000113436.16gold quality
brainUBERON:000095536.03gold quality
right frontal lobeUBERON:000281035.81silver quality
bone marrowUBERON:000237135.04gold quality
putamenUBERON:000187434.40silver quality
muscle tissueUBERON:000238534.22gold quality
adrenal tissueUBERON:001830333.01gold quality
duodenumUBERON:000211432.46gold quality
hindlimb stylopod muscleUBERON:000425232.15gold quality
leukocyteCL:000073831.51gold quality
urinary bladderUBERON:000125531.34gold quality
endometriumUBERON:000129531.28gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

ExperimentMarker?Max mean expression
E-ANND-3yes2.78

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 4)

  • Northern blot analysis reveals expression of galanin-receptor like (GalRL) in the central nervous system with minor levels in peripheral organs and tissues, such as testis, liver, kidney and stomach. (PMID:15111018)
  • These data identify GPR151 as a critical modulator of habenular function that controls nicotine addiction vulnerability (PMID:32098843)
  • Expression of Proton-Sensitive GPR31, GPR151, TASK1 and TASK3 in Common Skin Tumors. (PMID:35011589)
  • Analyzing human knockouts to validate GPR151 as a therapeutic target for reduction of body mass index. (PMID:35381001)

Cross-species orthologs

3 orthologs

OrganismSymbolGene ID
danio_rerioGPR151ENSDARG00000104291
mus_musculusGpr151ENSMUSG00000042816
rattus_norvegicusGpr151ENSRNOG00000027103

Paralogs (7): GPR174 (ENSG00000147138), GPR146 (ENSG00000164849), GPR183 (ENSG00000169508), RXFP3 (ENSG00000182631), GPR132 (ENSG00000183484), GPR141 (ENSG00000187037), P2RY11 (ENSG00000244165)

Protein

Protein identifiers

G-protein coupled receptor 151 — Q8TDV0 (reviewed: Q8TDV0)

Alternative names: G-protein coupled receptor PGR7, GPCR-2037, Galanin receptor 4, Galanin-receptor-like protein

All UniProt accessions (1): Q8TDV0

UniProt curated annotations — full annotation on UniProt →

Function. Proton-sensing G-protein coupled receptor.

Subcellular location. Cell membrane.

Tissue specificity. High expression in the spinal cord.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_919227* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR000276GPCR_RhodpsnFamily
IPR017452GPCR_Rhodpsn_7TMDomain

Pfam: PF00001

UniProt features (25 total): topological domain 8, transmembrane region 7, sequence variant 3, compositionally biased region 2, glycosylation site 2, chain 1, region of interest 1, disulfide bond 1

Structure

Experimental structures (PDB)

2 structures.

PDBMethodResolution (Å)
9W3LELECTRON MICROSCOPY2.76
9W3KELECTRON MICROSCOPY3.08

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q8TDV0-F178.960.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 111–187

Glycosylation sites (2): 10, 15

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 70 (showing top): GOBP_REGULATION_OF_EXOCYTOSIS, GOBP_NEUROTRANSMITTER_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_EXOCYTOSIS, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_RESPONSE_TO_ISCHEMIA, GOBP_REGULATION_OF_NEUROTRANSMITTER_TRANSPORT, GOBP_SECRETION, GOBP_REGULATION_OF_REGULATED_SECRETORY_PATHWAY, GOBP_SIGNAL_RELEASE, GOBP_SYNAPTIC_SIGNALING, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS, GOBP_RESPONSE_TO_PH

GO Biological Process (6): response to ischemia (GO:0002931), G protein-coupled receptor signaling pathway (GO:0007186), response to acidic pH (GO:0010447), positive regulation of immune response (GO:0050778), regulation of synaptic vesicle exocytosis (GO:2000300), signal transduction (GO:0007165)

GO Molecular Function (3): G protein-coupled receptor activity (GO:0004930), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (5): plasma membrane (GO:0005886), synaptic vesicle membrane (GO:0030672), presynaptic membrane (GO:0042734), cholinergic synapse (GO:0098981), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
response to stress1
G protein-coupled receptor activity1
signal transduction1
response to pH1
positive regulation of immune system process1
immune response1
positive regulation of response to stimulus1
regulation of immune response1
synaptic vesicle exocytosis1
regulation of neurotransmitter secretion1
regulation of regulated secretory pathway1
cell communication1
cellular process1
signaling1
regulation of cellular process1
cellular response to stimulus1
transmembrane signaling receptor activity1
G protein-coupled receptor signaling pathway1
protein binding1
binding1
membrane1
cell periphery1
synaptic vesicle1
exocytic vesicle membrane1
synaptic membrane1
presynapse1
synapse1
cellular anatomical structure1

Protein interactions and networks

STRING

548 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
GPR151GALP22466836
GPR151CCDC183Q5T5S1599
GPR151GPR139Q6DWJ6573
GPR151GPR75O95800528
GPR151GPR31O00270489
GPR151SH3RF2Q8TEC5489
GPR151GPR176Q14439479
GPR151GPR132Q9UNW8465
GPR151GPR149Q86SP6462
GPR151GPR68Q15743461
GPR151KCNS2Q9ULS6442
GPR151GPR88Q9GZN0440
GPR151CCKBRP32239432
GPR151HAPLN4Q86UW8428
GPR151GPR65Q8IYL9420

IntAct

129 interactions, top by confidence:

ABTypeScore
TUSC5GPR151psi-mi:“MI:0915”(physical association)0.600
NRMGPR151psi-mi:“MI:0915”(physical association)0.560
STX8GPR151psi-mi:“MI:0915”(physical association)0.560
GPR151SSMEM1psi-mi:“MI:0915”(physical association)0.560
CDIPTGPR151psi-mi:“MI:0915”(physical association)0.560
GPR151SLC18A2psi-mi:“MI:0915”(physical association)0.560
KEAP1GPR151psi-mi:“MI:0915”(physical association)0.560
GPR151CREB3L1psi-mi:“MI:0915”(physical association)0.560
GPR151psi-mi:“MI:0915”(physical association)0.560
SLC18A2GPR151psi-mi:“MI:0915”(physical association)0.560
UNC93AGPR151psi-mi:“MI:0915”(physical association)0.560
LATGPR151psi-mi:“MI:0915”(physical association)0.560
ARL6IP1GPR151psi-mi:“MI:0915”(physical association)0.560
AQP6GPR151psi-mi:“MI:0915”(physical association)0.560
IGFBP5GPR151psi-mi:“MI:0915”(physical association)0.560
SLC10A1GPR151psi-mi:“MI:0915”(physical association)0.560
GPR151SLC41A2psi-mi:“MI:0915”(physical association)0.560
GPR151BCL2L2psi-mi:“MI:0915”(physical association)0.560
GPR151CGRRF1psi-mi:“MI:0915”(physical association)0.560
GPR151SACM1Lpsi-mi:“MI:0915”(physical association)0.560
GPR151MANBALpsi-mi:“MI:0915”(physical association)0.560
GPR151TIMMDC1psi-mi:“MI:0915”(physical association)0.560
GPR151ERGIC3psi-mi:“MI:0915”(physical association)0.560

BioGRID (52): GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid), GPR151 (Two-hybrid)

ESM2 similar proteins: A2BGS3, A6NGA9, E7F594, O36364, O60478, O60883, O95800, O95838, P03208, P16849, P31389, P34590, P35367, P49219, Q03613, Q09351, Q09964, Q09965, Q14439, Q16950, Q16951, Q2KI97, Q3U3F9, Q5FVG1, Q5IXF8, Q5UAW9, Q60755, Q64017, Q66615, Q66H29, Q6P7G9, Q6SW98, Q6X632, Q7TSN5, Q7TSN6, Q80W35, Q80WT4, Q8BNQ3, Q8C206, Q8CIM5

Diamond homologs: Q7TSN5, Q7TSN6, Q8TDV0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance76
Likely benign5
Benign1

Top pathogenic / likely-pathogenic (0)

SpliceAI

11 predictions. Top by Δscore:

VariantEffectΔscore
5:146515190:C:CTacceptor_gain0.7700
5:146515215:G:GAacceptor_gain0.4200
5:146515216:A:AAacceptor_gain0.4200
5:146515217:A:AAacceptor_gain0.4200
5:146515193:A:Tacceptor_gain0.2700
5:146515221:ATG:Aacceptor_gain0.2500
5:146515111:ACTCT:Aacceptor_gain0.2300
5:146515214:T:TGacceptor_gain0.2300
5:146515118:G:Aacceptor_gain0.2200
5:146515498:AGAG:Adonor_gain0.2100
5:146514867:T:Adonor_gain0.2000

AlphaMissense

2753 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
5:146515736:G:CS126R0.983
5:146515736:G:TS126R0.983
5:146515738:T:GS126R0.983
5:146515782:C:GC111S0.978
5:146515783:A:TC111S0.978
5:146515871:G:CS81R0.974
5:146515871:G:TS81R0.974
5:146515873:T:GS81R0.974
5:146514947:A:CF389L0.972
5:146514947:A:TF389L0.972
5:146514949:A:GF389L0.972
5:146515782:C:TC111Y0.972
5:146515630:A:GW162R0.971
5:146515630:A:TW162R0.971
5:146515802:C:AW104C0.971
5:146515802:C:GW104C0.971
5:146515554:C:GC187S0.970
5:146515555:A:TC187S0.970
5:146515783:A:GC111R0.966
5:146515555:A:GC187R0.962
5:146515781:G:CC111W0.962
5:146515966:C:GG50R0.962
5:146515877:A:CN79K0.960
5:146515877:A:TN79K0.960
5:146515315:A:GW267R0.959
5:146515315:A:TW267R0.959
5:146514893:C:AW407C0.954
5:146514893:C:GW407C0.954
5:146515553:G:CC187W0.952
5:146515975:A:GC47R0.951

dbSNP variants (sampled 300 via entrez): RS1000003124 (5:146517171 T>C), RS1000706697 (5:146513539 C>G), RS1001181333 (5:146513677 A>G), RS1001281966 (5:146512747 T>C), RS1002021721 (5:146514556 C>T), RS1002088159 (5:146513073 A>C), RS1003610712 (5:146517577 T>A), RS1004452677 (5:146517997 T>C), RS1004509023 (5:146513101 A>G), RS1004582526 (5:146513420 C>T), RS1004827206 (5:146517797 C>T), RS10061188 (5:146512733 G>A,C), RS1006179849 (5:146514694 C>A,G,T), RS10062873 (5:146516774 A>C,G), RS1006918050 (5:146516176 C>G,T)

Disease associations

OMIM: gene MIM:618487 | disease phenotypes: MIM:190300

GenCC curated gene-disease

Mondo (1): essential tremor (MONDO:0003233)

Orphanet (1): NON RARE IN EUROPE: Hereditary essential tremor (Orphanet:862)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

StudyTraitp-value
GCST008359_7Response to cognitive-behavioural therapy in anxiety disorder4.000000e-06

EFO canonical traits (1, from GWAS)

EFO IDTrait name
EFO:0007820cognitive behavioural therapy

MeSH disease descriptors (1)

DescriptorNameTree numbers
D020329Essential TremorC10.228.662.350

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3085617 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with emerging pharmacology

CTD chemical–gene interactions

1 total (human), top 1 by PubMed support.

ChemicalActions (top 5)PubMed papers
Benzo(a)pyreneincreases methylation1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL3089342BindingAgonist activity at GPR151 (unknown origin) expressed in CHO-K1 cells at 10 uM after 90 to 180 mins by beta-arrestin assay relative to controlIdentification of CB1/CB2 ligands from Zanthoxylum bungeanum. — J Nat Prod

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

CellosaurusNameCategorySex
CVCL_KX41PathHunter CHO-K1 GPR151 beta-arrestinSpontaneously immortalized cell lineFemale

Clinical trials (associated diseases)

235 trials via MONDO — disease-level, not drug-specific.

TrialPhaseStatusTitle
NCT00439699PHASE4COMPLETEDA Pilot Clinical Trial Of Memantine for Essential Tremor
NCT00584376PHASE4COMPLETEDPregabalin (Lyrica) for the Treatment of Essential Tremor
NCT00998660PHASE4COMPLETEDRECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
NCT02111369PHASE4COMPLETEDPropranolol and Botulinum Toxin for Essential Vocal Tremor
NCT02495883PHASE4COMPLETEDFunctional Imaging of Tremor Circuits and Mechanisms of Treatment Response
NCT00018564PHASE3COMPLETEDNovel Therapies for Essential Tremor
NCT00236496PHASE3COMPLETEDA Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
NCT01441284PHASE3WITHDRAWNEfficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
NCT04193527PHASE3COMPLETEDA Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
NCT04265209PHASE3COMPLETED[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson’s Diseases and Essential Tremor
NCT06087276PHASE3ENROLLING_BY_INVITATIONEssential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
NCT00080366PHASE2COMPLETEDOctanol to Treat Essential Tremor
NCT00102596PHASE2COMPLETEDClinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
NCT00223743PHASE2COMPLETEDA Safety/Efficacy Trial of Zonisamide for Essential Tremor
NCT00321087PHASE2TERMINATEDA Study of T2000 in Essential Tremor
NCT00598078PHASE2COMPLETEDMultiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
NCT00655278PHASE2TERMINATEDT2000 in Essential Tremor - Open Label Continuation
NCT01332695PHASE2COMPLETEDA Pilot Efficacy and Safety Study of ST101 in Essential Tremor
NCT02277106PHASE2COMPLETEDEvaluate SAGE-547 in Participants With Essential Tremor
NCT02551848PHASE2UNKNOWNKinematic-based BoNT-A Injections for Bilateral ET
NCT02668146PHASE2UNKNOWNAn Efficacy/Safety Study of Perampanel for Reducing Essential Tremor
NCT02978781PHASE2COMPLETEDA Study to Evaluate SAGE-217 in Participants With Essential Tremor
NCT03101241PHASE2COMPLETEDA Phase 2 RCT Study of CX-8998 for Essential Tremor
NCT03688685PHASE2COMPLETEDA Clinical Study to Evaluate CAD-1883 in Essential Tremor
NCT03780426PHASE2COMPLETEDtSMS in Essential Tremor
NCT04305275PHASE2COMPLETEDA Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
NCT04727658PHASE2TERMINATEDLinac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL)
NCT04880616PHASE2COMPLETEDSafety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
NCT05021978PHASE2COMPLETEDA Clinical Trial of PRAX-944 in Participants With Essential Tremor
NCT05021991PHASE2COMPLETEDA Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
NCT05122650PHASE2COMPLETEDA Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
NCT05173012PHASE2COMPLETEDStudy to Evaluate SAGE-324 in Participants With Essential Tremor
NCT05387642PHASE2WITHDRAWNA Clinical Trial of PRAX-114 in Participants With Essential Tremor
NCT06312800PHASE2WITHDRAWNAcamprosate and Methazolamide for Essential Tremor
NCT06821906PHASE2RECRUITINGStereotactic Radiosurgery in the Treatment of Essential Tremor
NCT07074002PHASE2RECRUITINGProof of Concept Study on BP1.4979 Effect on Essential Tremor
NCT07103265PHASE2NOT_YET_RECRUITINGDeveloping a New LIFU Neuromodulation Method to Suppress Tremor
NCT00001986PHASE1COMPLETED1-Octanol to Treat Essential Tremor
NCT00016679PHASE1COMPLETED1-Octanol to Treat Essential Tremor
NCT01304758PHASE1COMPLETEDExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor
  • Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): essential tremor

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 78

This page pulls from 78 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgtopdb_interactiongwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot